- Lyra is to report top line data of its Phase 2 Trial in December.
- All indications are the trial should be a success, and they have strong backing from Perceptive Advisors.
- The market isn't paying much attention to the company at present, but good data would bring new investors.
- There is a long way to go to approval, but potential peak sales for Lyra are multiples of the current enterprise value.
- The company's current value is underpinned significantly by its robust balance sheet.
For further details see:
Lyra Therapeutics: An Intriguing Risk/Reward Proposition Tackling Chronic Rhinosinusitis